Zhang Fengyu, Liu Ruilai, Liu Cheng, Zhang Haishi, Lu Yuan
Department of Laboratory Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Road, Jing-an District, Shanghai, 200040 China.
Department of Neurosurgery, Huashan Hospital, Fudan University, 12 Wulumuqi Road, Jing-an District, Shanghai, 200040 China.
Cancer Cell Int. 2020 May 26;20:197. doi: 10.1186/s12935-020-01272-1. eCollection 2020.
Radiotherapy, chemotherapy, and surgery have made crucial strides in glioblastoma treatment, yet they often fail; thus, new treatment and new detection methods are needed. Aberrant expression of Nanos3 has been functionally associated with various cancers. Here, we sought to identify the clinical significance and potential mechanisms of Nanos3 in human glioblastoma.
Nanos3 expression was studied in nude mouse glioblastoma tissues and glioblastoma cell lines by immunohistochemistry, Western blot, and RT-PCR. Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing assay was performed to generate the Nanos3 knockdown glioblastoma cell lines. The effects of Nanos3 on glioblastoma cells proliferation, migration, invasion, chemoresistance, germ cell characteristics, and tumor formation were analyzed by CCK8, transwell, cell survival experiments and alkaline phosphatase staining in vitro and in nude mouse models in vivo. Correlation between the expression of stemness proteins and the expression of Nanos3 was evaluated by Western blot.
We found that Nanos3 was strongly expressed in both glioblastoma cell lines and tissues. Western blot and sequencing assays showed that the Nanos3 knockdown glioblastoma cell lines were established successfully, and we discovered that Nanos3 deletion reduced the proliferation, migration, and invasion of glioblastoma cells in vitro (< 0.05). Nanos3 knockdown enhanced the sensitivity of glioblastoma cells to doxorubicin (DOX) and temozolomide (TMZ) (< 0.05), and Nanos3 glioblastoma cell lines did not show the characteristics of the germline cells. In addition, Nanos3 deletion inhibited subcutaneous xenograft tumor growth in vivo (< 0.001). Moreover, the oncogenesis germline protein levels of CD133, Oct4, Ki67, and Dazl decreased significantly in glioblastoma cells following Nanos3 knockdown.
Both in vitro and in vivo assays suggest that Nanos3, which is a cancer-germline gene, initiates the tumorigenesis of glioblastoma via acquiring the oncogenesis germline traits. These data demonstrate that ectopic germline traits are necessary for glioblastoma growth.
放射治疗、化学治疗和手术在胶质母细胞瘤治疗方面取得了重大进展,但它们常常失败;因此,需要新的治疗方法和检测方法。Nanos3的异常表达在功能上与多种癌症相关。在此,我们试图确定Nanos3在人类胶质母细胞瘤中的临床意义和潜在机制。
通过免疫组织化学、蛋白质免疫印迹法和逆转录-聚合酶链反应,研究裸鼠胶质母细胞瘤组织和胶质母细胞瘤细胞系中Nanos3的表达。进行成簇规律间隔短回文重复序列(CRISPR)-Cas9基因编辑试验,以生成Nanos3基因敲低的胶质母细胞瘤细胞系。通过CCK8、Transwell、细胞存活实验和碱性磷酸酶染色,在体外和体内裸鼠模型中分析Nanos3对胶质母细胞瘤细胞增殖、迁移、侵袭、化疗耐药性、生殖细胞特性和肿瘤形成的影响。通过蛋白质免疫印迹法评估干性蛋白表达与Nanos3表达之间的相关性。
我们发现Nanos3在胶质母细胞瘤细胞系和组织中均强烈表达。蛋白质免疫印迹法和测序分析表明,成功建立了Nanos3基因敲低的胶质母细胞瘤细胞系,并且我们发现Nanos3缺失降低了胶质母细胞瘤细胞在体外的增殖、迁移和侵袭能力(<0.05)。Nanos3基因敲低增强了胶质母细胞瘤细胞对多柔比星(DOX)和替莫唑胺(TMZ)的敏感性(<0.05),并且Nanos3胶质母细胞瘤细胞系未表现出生殖细胞的特征。此外,Nanos3缺失在体内抑制皮下异种移植瘤的生长(<0.001)。而且,在Nanos3基因敲低后的胶质母细胞瘤细胞中,CD133、Oct4、Ki67和Dazl的肿瘤发生生殖系蛋白水平显著降低。
体外和体内试验均表明,作为一种癌胚基因,Nanos3通过获得肿瘤发生生殖系特征启动胶质母细胞瘤的肿瘤发生。这些数据表明,异位生殖系特征是胶质母细胞瘤生长所必需的。